Gottlieb: hantavirus risk low, FDA turmoil looms, antidepressant debate
In a May 10 interview on Face the Nation, former FDA commissioner Scott Gottlieb says the hantavirus outbreak linked to a cruise ship presents low transmission risk but could yield additional cases as repatriations continue and the incubation window plays out; he criticizes ongoing leadership turnover and staff losses at the FDA, defends the continued use of antidepressants when properly prescribed and warns against abrupt stopping, and rejects ivermectin as an effective treatment while urging reliance on medical guidance.
